Mission Statement, Vision, & Core Values (2026) of Shenzhen New Industries Biomedical Engineering Co., Ltd.

Founded in Shenzhen in December 1995, Shenzhen New Industries Biomedical Engineering Co., Ltd. (Snibe) has grown into a global IVD leader whose mission-"Customer-centric, market-oriented, creating value for human health through continuous innovation"-drives a product portfolio that includes China's first automated chemiluminescence immunoassay analyzers and fully automatic CLIA systems, sold in more than 160 countries and regions; publicly listed on the Shenzhen Stock Exchange in May 2020 and boasting a market value near 60 billion yuan, Snibe pairs international quality credentials (ISO 9001 and ISO 13485) with a workforce of over 2,800 employees and recognition among Asia's 200 Best Under A Billion (2025), while its vision "To be the Pioneer in Global Diagnosis Field" and core values-"Assume Responsibility Bravely, Enjoy Challenge Persistently, Pursue Excellence Passionately"-underscore a culture focused on customer needs, relentless innovation, and measurable global expansion

Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ) - Intro

• Founded: December 1995 (Shenzhen, China)
• Listed: Shenzhen Stock Exchange, May 2020
• Global footprint: products sold in >160 countries and regions (as of late 2025)
• Employees: >2,800
• Certifications: ISO 9001, ISO 13485
• Recognition: Listed among Asia's 200 Best Under A Billion (2025)
• Market value: ~60 billion yuan (estimated, late 2025)

• Deliver reliable, high-performance clinical diagnostics that improve patient care and public health outcomes.
• Advance automation and reagent integration to increase laboratory efficiency and accessibility.
• Maintain rigorous quality and regulatory compliance to ensure product safety and trust.

• Be a global leader in smart, automated IVD solutions, enabling timely and accurate diagnostics everywhere.
• Drive innovation that bridges advanced biomedical engineering with scalable clinical application.
• Expand global market presence while fostering localized support and partnerships in target regions.

• Innovation - continuous R&D investment and first-mover engineering (e.g., development of China's first automated CLIA analyzer).
• Quality - adherence to ISO 9001 and ISO 13485 standards across product life cycles.
• Customer Focus - delivering complete analyzer + reagent solutions tailored to clinical workflows.
• Integrity - transparent governance aligned with public listing responsibilities and industry regulation.
• Collaboration - partnering with global distributors, clinical labs, and regulatory bodies to scale impact.

• R&D-driven product pipeline focused on automation, digital connectivity, and assay expansion for infectious disease, oncology, and endocrine testing.
• Geographic expansion - sustain and grow presence in >160 markets through regulatory approvals and local service networks.
• Manufacturing scale-up - continued investment in facilities and a new operations center to support higher volume and global logistics.
• Financial strength - maintain market capitalization and profitability metrics consistent with inclusion among Asia's 200 Best Under A Billion.

• Pioneer status: China's first automated chemiluminescence immunoassay analyzer; first domestically developed fully automatic CLIA analyzer.
• International compliance: ISO 9001 and ISO 13485 certified, supporting export and regulatory approvals across multiple jurisdictions.
• Recognition and scale: listed among Asia's 200 Best Under A Billion (2025); estimated market value ~60 billion yuan; distribution in over 160 countries.

Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ) - Overview

• Customer-centric: tailoring product portfolios and service models to laboratory and clinical workflows.
• Market-oriented: prioritizing segments with high unmet diagnostic demand and scalable adoption potential.
• Creating value for human health: focusing on accuracy, accessibility, and clinical relevance of diagnostic solutions.
• Continuous innovation: sustained investment in R&D and product lifecycle enhancement to address evolving disease burdens.

• Product roadmap alignment: prioritizing assays and platforms with high clinical utility and scalable manufacturing.
• Quality and compliance: maintaining certifications and regulatory clearances across key markets to ensure patient safety.
• Customer feedback loops: structured post-sale support and field data integration to refine product features and service offerings.
• Partnerships and channels: expanding distribution and service networks to increase accessibility in emerging and established markets.

Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ) - Mission Statement

• Pioneer: prioritizes breakthrough assay platforms, novel biomarkers, and integrated diagnostics devices to set clinical and industry standards.
• Global Diagnosis Field: commits to broad geographic penetration-scaling from domestic leadership in China to sustained growth in Asia, Europe, Africa, Latin America, and the Middle East.
• Strategic alignment: R&D-driven product diversification, regulatory approvals (CE/IVD, Emergency Use Authorizations), and partnerships to accelerate market entry.
• Cultural impact: uses the vision as an internal rallying point to foster a forward-thinking, innovation-first employee mindset.

• Internationalization: accelerating approvals and local partnerships to convert export penetration into sustained market share abroad.
• Product diversification: expanding immunoassay, molecular diagnostics, POCT, and integrated health-screening solutions to address hospital, laboratory, and decentralized care settings.
• R&D leverage: maintain R&D intensity (~8-10% of revenue) to move from incremental improvements toward platform-level innovations that create defensible competitive advantages.
• Commercial scale: increase installed base and consumable attach rates to generate recurring revenue and margin stability.

• Employees: clear R&D and market targets drive talent recruitment, retention, and performance incentives tied to innovation outcomes.
• Investors: growth story centers on recurring consumables revenue, international expansion, and margin accretion from platform scale-refer to financial analysis for deeper metrics: Breaking Down Shenzhen New Industries Biomedical Engineering Co., Ltd. Financial Health: Key Insights for Investors
• Customers and clinicians: focus on diagnostic accuracy, throughput, and integrated solutions to improve clinical workflows and patient outcomes.
• Partners and regulators: collaborative approach to approvals, distribution, and localized service to accelerate uptake in diverse healthcare systems.

Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ) - Vision Statement

• Global clinical impact: expand presence in key international markets while strengthening domestic leadership in China's fast-growing IVD sector.
• Technology-driven growth: continuous investment in R&D to advance immunoassay, molecular diagnostics and digital laboratory solutions.
• Patient-centred accessibility: shorten diagnostic pathways and lower per-test costs to broaden access across healthcare tiers.

• Assume Responsibility Bravely - encourages individual ownership of outcomes, rapid decision-making in product development and accountability in quality and regulatory compliance.
• Enjoy Challenge Persistently - frames regulatory hurdles, technological uncertainty and market competition as opportunities for learning and iteration; fosters resilience in teams.
• Pursue Excellence Passionately - drives rigorous quality systems, continuous process improvement and clinical validation to meet international standards.

• Leadership and training: mandatory value-alignment programs for managers and new hires, with measurable KPIs tied to adoption of core behaviors.
• Performance management: career progression and incentive structures reward responsibility-taking, effective risk management, and demonstrable quality improvements.
• Culture metrics: periodic employee engagement surveys and leadership 360 reviews track value integration and inform targeted interventions.

• Structured R&D pipelines with stage gates that enforce accountability and quality at each step.
• Cross-functional "challenge teams" that tackle high-risk product launches, rewarded for learning outcomes as well as commercial success.
• Quality management systems and clinical partnerships to validate performance against international benchmarks (e.g., CE, other regional approvals).